Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48061

UPID:
SDF1_HUMAN

ALTERNATIVE NAMES:
C-X-C motif chemokine 12; Intercrine reduced in hepatomas; Pre-B cell growth-stimulating factor

ALTERNATIVE UPACC:
P48061; B2R4G0; E7EVL0; H7BYN8; Q2L985; Q2L986; Q2L988; Q5IT36; Q6ICW0; Q9H554

BACKGROUND:
The protein Stromal cell-derived factor 1, with alternative names such as Intercrine reduced in hepatomas and Pre-B cell growth-stimulating factor, is crucial for embryonic development, B-cell lymphopoiesis, and myelopoiesis. It binds to CXCR4 and ACKR3 receptors, modulating monocyte and T-lymphocyte migration, and plays a protective role in myocardial infarction by influencing integrin activation and cell adhesion processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Stromal cell-derived factor 1 offers a promising avenue for developing novel therapeutic approaches. Its capacity to regulate immune cell migration and contribute to heart repair post-infarction presents a valuable target for drug discovery in treating inflammatory and cardiovascular conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.